Medicare premiums to remain unchanged after Aduhelm price cut spurs review

Medicare Part B premiums will remain the same this year even after Department of Health and Human Services Secretary Xavier Becerra called for a review following drugmaker Biogen’s decision to cut the price of its Alzheimer’s drug Aduhelm, which had led to this year’s premium hike.